However, at lower antigen doses there was a requirement ... First, should syngeneic or allogeneic dendritic cells be used for tumor peptide presentation? Mature, syngeneic dendritic cells have ...

Receptors on the surface of cytotoxic T cells recognize peptides presented by major histocompatibility complex (MHC) molecules on the tumor cell membrane. CD8 acts as a T-cell co-receptor that ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

The findings could pave the way for more effective immunotherapy strategies, Zhang said. "In this study, we also identified several peptide antigens that are more highly expressed in cancer cells ...

The quest for such tumor-specific antigens (TSAs) has largely focused on predicting mutated peptides from cancer cell genomes of individual patients. This approach makes a research project out of each ...

Interesting targets for peptide vaccination have been defined including Wilms tumor gene 1 ... For the three aforementioned antigens, more and more epitope peptides have been defined.

A team of scientists has developed a groundbreaking approach using specially designed peptides to improve drug formulations. This innovative method significantly enhances anti-tumor efficacy ...

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could ...

Furthermore, these ncORF-derived peptides were also more likely to be unstable unless they were bound to HLA-I antigens in ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...